Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06787066 · ClinicalTrials.gov registry record · Early Phase 1
Sympathetic Vascular Transduction Across the Menopause Transition: Contributing Mechanisms
A Early Phase 1 study of Menopause, sponsored by University of Missouri-Columbia.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT06787066: Recruiting Early Phase 1 study of Menopause, sponsored by University of Missouri-Columbia.
NCT06787066 is a Early Phase 1 study of Menopause that is actively recruiting participants, run by University of Missouri-Columbia. The registered enrollment target is 75 participants, below the 9,393-participant average among 54 other Menopause trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06787066, a Early Phase 1 study of Menopause, is actively recruiting participants, sponsored by University of Missouri-Columbia.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators aim to assess the interactions between the sympathetic nervous system and the vasculature in women across the menopause transition to better understand why aging women have a higher risk of cardiovascular disease.
Primary Outcome
Assessing the relative change in blood flow (Doppler ultrasound) following an increase in sympathetic nerve activity.
Conditions Studied
Interventions
- DRUG Propranolol Hydrochloride
- DRUG Phentolamine Injection
Study Locations (1)
Missouri
- University of Missouri - Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2025-07-10 |
| Est. Completion | 2026-12 |
| Phase | Early Phase 1 |
What NCT06787066 shows while recruiting
NCT06787066 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 9,393-participant average among 54 other Menopause trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Menopause appearing as the primary indexed condition, and to 2 interventions - of which Propranolol Hydrochloride is the first listed.
NCT06787066 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT06787066 about?
NCT06787066 is a clinical study titled "Sympathetic Vascular Transduction Across the Menopause Transition: Contributing Mechanisms". The investigators aim to assess the interactions between the sympathetic nervous system and the vasculature in women across the menopause transition to better understand why aging women have a higher risk of cardiovascular disease.
What is the current status of trial NCT06787066?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 75 participants. The study started on 2025-07-10. Estimated completion is 2026-12.
What conditions does trial NCT06787066 study?
This clinical trial studies the following conditions: Menopause.
What interventions are being tested in trial NCT06787066?
The interventions under investigation include: Propranolol Hydrochloride (DRUG), Phentolamine Injection (DRUG).
Who is sponsoring clinical trial NCT06787066?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06787066 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Menopause
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06787066's enrollment target sits among peer trials
75 25th of 54 higher than 29 of 54 other Menopause trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Menopause trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of Early Aging and Menopause on the Vascular Responses to Hypoxia
RECRUITING · Early Phase 1
-
MitoQ and Exercise Effects on Vascular Health
ACTIVE NOT RECRUITING · Early Phase 1
-
Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women
COMPLETED · Early Phase 1
-
Menopause Transition, Sex Hormone Deficiency and Autonomic and Vascular Function
RECRUITING
-
Autonomic Regulation of Blood Pressure in Premature and Early Menopausal Women
RECRUITING
-
Apple Women's Health Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI